Correction to: Exploring the efficacy of an electronic symptom assessment and self-care intervention to preserve physical function in individuals receiving neurotoxic chemotherapy

Correction to: Knoerl et al. BMC Cancer (2018) 18:1203

https://0-doi-org.brum.beds.ac.uk/10.1186/s12885-018-5093-z

Following publication of the original article [1], the authors reported that the chemotherapy dosages in the footnote of Table 1 should be in mg, and not mg/m².

The footnote for Table 1 should read as follows:

This table describes the demographic characteristics of the patients at baseline.

^aTo compare distribution of cancer diagnosis for intervention versus control, the diagnoses with < 10 observations are grouped together into another category (i.e., esophageal, testicular, gastrointestinal, miscellaneous, sarcoma, bladder, gastric, pancreatic and unknown primary).

^bFor participants receiving multiple neurotoxic chemotherapy agents, dose category was determined based on the highest dose of one of the specific agents they were receiving.

^cPaclitaxel < 700 mg; Oxaliplatin < 800 mg; Docetaxel < 300 mg; Cisplatin < 300 mg.

^dPaclitaxel 700–1400 mg; Oxaliplatin 800–1000 mg; Docetaxel 300–600 mg; Cisplatin 300–600 mg.

^ePaclitaxel > 1400 mg; Oxaliplatin > 1000 mg; Docetaxel > 600 mg; Cisplatin > 600 mg.

^fNeurotoxic chemotherapy dose reduction due to other symptom-related causes included fatigue, pain, skin changes, bowel problems, or breathing problems.